[ad_1]
According to the report, the first phase of the study, which involved 216 people, found that despite the absence of serious side effects, antibodies developed in vaccinated organisms interfere with HIV diagnosis and lead to erroneous results in some HIV tests. .
In light of this, CSL, together with the Australian government, decided to discontinue further testing of these vaccines.
“This result reveals risks in the early stages of vaccine development,” said Andrew Nash, CSL’s principal research expert.
According to him, the Australian COVID-19 vaccine could be improved, but it could take up to 12 months.
Instead, CSL plans to produce another 20 million. The doses of the vaccine developed by AstraZeneca are in addition to the 30 million already produced. and the Australian government intends to increase the order for Novavax.
Earlier it was announced that the American biotech company Novavax had signed a preliminary agreement with the Australian government, setting the terms for the 40 million. expected delivery of COVID-19 vaccine.
It is not allowed to publish, quote or reproduce the information of the BNS news agency in the media and on websites without the written consent of the UAB “BNS”.
[ad_2]
